Marianne D Sadar

List of Publications by Year
in descending order

103 papers	5,599 citations	87723 38 h-index	79541 73 g-index
104 all docs	104 docs citations	104 times ranked	5850 citing authors

#	Article	IF	Citations
1	Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor. Cancer Cell, 2010, 17, 535-546.	7.7	452
2	Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways. Journal of Biological Chemistry, 2002, 277, 7076-7085.	1.6	326
3	CELL LINES USED IN PROSTATE CANCER RESEARCH: A COMPENDIUM OF OLD AND NEW LINESâ€"PART 1. Journal of Urology, 2005, 173, 342-359.	0.2	308
4	Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells. Journal of Biological Chemistry, 2002, 277, 38087-38094.	1.6	264
5	An androgen receptor N-terminal domain antagonist for treating prostate cancer. Journal of Clinical Investigation, 2013, 123, 2948-2960.	3.9	262
6	Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways. Journal of Biological Chemistry, 1999, 274, 7777-7783.	1.6	237
7	Androgenic Induction of Prostate-specific Antigen Gene Is Repressed by Protein-Protein Interaction between the Androgen Receptor and AP-1/c-Jun in the Human Prostate Cancer Cell Line LNCaP. Journal of Biological Chemistry, 1997, 272, 17485-17494.	1.6	184
8	Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC Genomics, 2006, 7, 246.	1.2	173
9	Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate, 2005, 64, 149-159.	1.2	162
10	CELL LINES USED IN PROSTATE CANCER RESEARCH: A COMPENDIUM OF OLD AND NEW LINESâ€"PART 2. Journal of Urology, 2005, 173, 360-372.	0.2	145
11	Small Molecule Inhibitors Targeting the â€œAchilles' Heelâ€• of Androgen Receptor Activity. Cancer Research, 2011, 71, 1208-1213.	0.4	137
12	Crosstalk between the Androgen Receptor and Î²-Catenin in Castrate-Resistant Prostate Cancer. Cancer Research, 2008, 68, 9918-9927.	0.4	131
13	Sintokamides A to E, Chlorinated Peptides from the Sponge <i>Dysidea</i> sp. that Inhibit Transactivation of the N-Terminus of the Androgen Receptor in Prostate Cancer Cells. Organic Letters, 2008, 10, 4947-4950.	2.4	130
14	Prostate cancer: molecular biology of early progression to androgen independence.. Endocrine-Related Cancer, 1999, 6, 487-502.	1.6	128
15	An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Laboratory Investigation, 2005, 85, 1392-1404.	1.7	107
16	Novel Biomarkers for Prostate Cancer Including Noncoding Transcripts. American Journal of Pathology, 2009, 175, 2264-2276.	1.9	107
17	Identification of Serum Amyloid A as a Biomarker to Distinguish Prostate Cancer Patients with Bone Lesions. Clinical Chemistry, 2005, 51, 695-707.	1.5	105
18	Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. Frontiers in Endocrinology, 2017, 8, 2.	1.5	100

#	Article	IF	Citations
19	Androgen receptor and its splice variants in prostate cancer. Cellular and Molecular Life Sciences, 2011, 68, 3971-3981.	2.4	90
20	Protein Profiling of Microdissected Prostate Tissue Links Growth Differentiation Factor 15 to Prostate Carcinogenesis. Cancer Research, 2004, 64, 5929-5933.	0.4	89
21	<i>ASAP1</i>, a Gene at 8q24, Is Associated with Prostate Cancer Metastasis. Cancer Research, 2008, 68, 4352-4359.	0.4	87
22	Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2016, 22, 4466-4477.	3.2	87
23	Androgen receptor decoy molecules block the growth of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1331-1336.	3.3	82
24	Characterization of 5Î±-reductase gene expression in stroma and epithelium of human prostate. Journal of Steroid Biochemistry and Molecular Biology, 1996, 59, 397-404.	1.2	79
25	Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries. BMC Genomics, 2009, 10, 476.	1.2	75
26	LNCaP Atlas: Gene expression associated with in vivoprogression to castration-recurrent prostate cancer. BMC Medical Genomics, 2010, 3, 43.	0.7	73
27	Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene, 2006, 25, 7311-7323.	2.6	72
28	Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection. Journal of Clinical Oncology, 2009, 27, 2787-2792.	0.8	68
29	Androgen receptor targeted therapies in castrationâ€resistant prostate cancer: Bench to clinic. International Journal of Urology, 2016, 23, 654-665.	0.5	65
30	Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells. Clinical Cancer Research, 2004, 10, 1860-1869.	3.2	64
31	Niphatenones, Glycerol Ethers from the Sponge <i>Niphates digitalis</i> Block Androgen Receptor Transcriptional Activity in Prostate Cancer Cells: Structure Elucidation, Synthesis, and Biological Activity. Journal of Medicinal Chemistry, 2012, 55, 503-514.	2.9	60
32	Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. Oncologist, 2016, 21, 1427-1435.	1.9	60
33	Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics, 2004, 4, 1116-1134.	1.3	58
34	Nâ€terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Molecular Oncology, 2015, 9, 628-639.	2.1	52
35	Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2016, 22, 2744-2754.	3.2	52
36	Phenobarbital Induction of Gene Expression in a Primary Culture of Rainbow Trout Hepatocytes. Journal of Biological Chemistry, 1996, 271, 17635-17643.	1.6	51

#	Article	IF	Citations
37	Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain. Journal of Biological Chemistry, 2016, 291, 22231-22243.	1.6	47
38	Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor. Expert Opinion on Drug Discovery, 2020, 15, 551-560.	2.5	45
39	Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. Research and Reports in Urology, 2018, Volume 10, 23-32.	0.6	42
40	Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain. PLoS ONE, 2014, 9, e107991.	1.1	35
41	Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. World Journal of Urology, 2012, 30, 311-318.	1.2	33
42	Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. , 1998, 69, 271-281.		31
43	Development of metastatic and nonâ€metastatic tumor lines from a patient's prostate cancer specimenâ€"identification of a small subpopulation with metastatic potential in the primary tumor. Prostate, 2010, 70, 1636-1644.	1.2	31
44	Order within a Disordered Structure. Structure, 2018, 26, 4-6.	1.6	31
45	Combination therapy with androgen receptor Nâ€terminal domain antagonist EPIâ€7170 and enzalutamide yields synergistic activity in ARâ€V7â€positive prostate cancer. Molecular Oncology, 2020, 14, 2455-2470.	2.1	31
46	Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer. Journal of Cellular Biochemistry, 2006, 98, 36-53.	1.2	30
47	FUS/TLS Is a Co-Activator of Androgen Receptor in Prostate Cancer Cells. PLoS ONE, 2011, 6, e24197.	1.1	29
48	Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. Molecular Cancer Therapeutics, 2002, 1, 629-37.	1.9	24
49	Interleukin-4 in patients with prostate cancer. Anticancer Research, 2005, 25, 4595-8.	0.5	24
50	Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. Cancer Letters, 2010, 292, 176-185.	3.2	22
51	Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants. Cancers, 2020, 12, 1991.	1.7	21
52	Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. ACS Pharmacology and Translational Science, 2019, 2, 453-467.	2.5	20
53	Androgens and androgen receptor in prostate and ovarian malignancies. Frontiers in Bioscience - Landmark, 2003, 8, D780-800.	3.0	20
54	Phenobarbital Induction of Cytochrome P4501A1 Is Regulated by cAMP-Dependent Protein Kinase-Mediated Signaling Pathways in Rainbow Trout Hepatocytes. Biochemical and Biophysical Research Communications, 1996, 225, 455-461.	1.0	19

#	Article	IF	Citations
55	Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.. Journal of Clinical Oncology, 2019, 37, 257-257.	0.8	19
56	14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens. Cancer Letters, 2007, 254, 137-145.	3.2	18
57	Promotion of growth in diploid and triploid coho salmon with parenteral delivery of a recombinant porcine somatotropin. Aquatic Living Resources, 1991, 4, 155-160.	0.5	17
58	Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy. Journal of Clinical Medicine, 2018, 7, 444.	1.0	17
59	Keys to unlock androgen receptor translocation. Journal of Biological Chemistry, 2019, 294, 8711-8712.	1.6	17
60	An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. JCI Insight, 2016, 1, .	2.3	16
61	Induction of CYP1A1 by GABA Receptor Ligands. Biochemical and Biophysical Research Communications, 1996, 229, 231-237.	1.0	15
62	A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells. Genomics, 2006, 87, 633-637.	1.3	15
63	Molecular analysis and characterization of PrEc, commercially available prostate epithelial cells. In Vitro Cellular and Developmental Biology - Animal, 2006, 42, 33-39.	0.7	15
64	Osteoblast-Derived Factors Induce an Expression Signature that Identifies Prostate Cancer Metastasis and Hormonal Progression. Cancer Research, 2009, 69, 3433-3442.	0.4	15
65	A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.. Journal of Clinical Oncology, 2015, 33, TPS5072-TPS5072.	0.8	15
66	Incarnatapeptins A and B, Nonribosomal Peptides Discovered Using Genome Mining and ¹H/¹⁵N HSQC-TOCSY. Organic Letters, 2020, 22, 4053-4057.	2.4	14
67	Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cellscience, 2006, 3, 61-81.	0.3	13
68	Spongian Diterpenoids Inhibit Androgen Receptor Activity. Molecular Cancer Therapeutics, 2013, 12, 621-631.	1.9	12
69	Large scale phosphoproteome analysis of LNCaP human prostate cancer cells. Molecular BioSystems, 2012, 8, 2174.	2.9	11
70	REGULATION OF CYTOCHROME P450 IN A PRIMARY CULTURE OF RAINBOW TROUT HEPATOCYTES. In Vitro Cellular and Developmental Biology - Animal, 2001, 37, 180.	0.7	10
71	Structureâ€“Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer. Journal of Natural Products, 2021, 84, 797-813.	1.5	10
72	Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones. Human Cell, 2021, 34, 211-218.	1.2	10

#	Article	IF	Citations
73	Pin1 inhibition improves the efficacy of ralaniten compounds that bind to the N-terminal domain of androgen receptor. Communications Biology, 2021, 4, 381.	2.0	10
74	Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer. PLoS ONE, 2017, 12, e0174134.	1.1	10
75	Picrotoxin Is a CYP1A1 Inducer in Rainbow Trout Hepatocytes. Biochemical and Biophysical Research Communications, 1995, 214, 1060-1066.	1.0	9
76	Does increased expression of glucocorticoid receptor support application of antagonists to this receptor for the treatment of castration resistant prostate cancer?. AME Medical Journal, 2018, 3, 66-66.	0.4	7
77	Abstract B117: Treatment of castrated resistant prostate cancer with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor. Molecular Cancer Therapeutics, 2019, 18, B117-B117.	1.9	7
78	Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptorâ€“positive Prostate and Breast Cancers. Molecular Cancer Therapeutics, 2022, 21, 294-309.	1.9	7
79	EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. Annals of Oncology, 2019, 30, v189-v190.	0.6	6
80	Uptake of Selected Organochlorine Contaminants in Fishes Resident in the Fraser River Estuary, Vancouver, British Columbia. Water Quality Research Journal of Canada, 1992, 27, 733-750.	1.2	5
81	Abstract 610: Preclinical evaluation of novel androgen receptor N-terminal domain inhibitor EPI-002 for the treatment of castration-resistant prostate cancer. Cancer Research, 2014, 74, 610-610.	0.4	4
82	Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1. Cancers, 2022, 14, 386.	1.7	4
83	Novel expressed sequences identified in a model of androgen independent prostate cancer. BMC Genomics, 2007, 8, 32.	1.2	3
84	Androgen-Responsive Gene Expression in Prostate Cancer Progression. , 2013, , 135-153.		2
85	Next generation N-terminal domain androgen receptor inhibitors with improved potency and metabolic stability in castration-resistant prostate cancer models.. Journal of Clinical Oncology, 2019, 37, 220-220.	0.8	2
86	MOLECULAR ANALYSIS AND CHARACTERIZATION OF PrEC, COMMERCIALLY AVAILABLE PROSTATE EPITHELIAL CELLS. In Vitro Cellular and Developmental Biology - Animal, 2006, 42, 33.	0.7	1
87	MP83-06 COMBINATION THERAPY WITH EPI-002 AND PARP INHIBITOR FOR CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.2	1
88	The Role of Cyclic AMP in Regulating the Androgen Receptor. , 2009, , 465-503.		1
89	Development of an imaging approach to detect splice variants of androgen receptor in prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5058-5058.	0.8	1
90	Abstract 1292: A new generation of N-terminal domain androgen receptor inhibitors, with improved pharmaceutical properties, in castration-resistant prostate cancer models. , 2019, , .		1

#	Article	IF	Citations
91	ANDROGEN RECEPTOR SUPPRESSES THE EXPRESSION OF SESN1, A POTENTIAL TUMOR SUPPRESSOR. Journal of Urology, 2008, 179, 104-104.	0.2	0
92	MP24-02 DEVELOPMENT OF AN IMAGING APPROACH TO DETECT SPLICE VARIANTS OF ANDROGEN RECEPTOR IN PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	0
93	MP61-12 AN ANDROGEN RECEPTOR SPLICE VARIANT-TARGETED COMBINATION THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER USING EPI-002 AND A PI3K/MTOR DUAL INHIBITOR. Journal of Urology, 2015, 193, .	0.2	0
94	Proteomics and Prostate Cancer. , 2015, , 143-174.		0
95	MP66-07 TARGETING ANDROGEN RECEPTOR N-TERMINAL DOMAIN FOR PROSTATE CANCER IMAGING AND THERAPY. Journal of Urology, 2015, 193, .	0.2	0
96	Developing Inhibitors to the Amino-Terminus Domains of Steroid Hormone Receptors. , 2021, , 613-642.		0
97	Androgen Receptors in the Pathology of Disease. , 2021, , 411-461.		0
98	Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation. Translational Cancer Research, 2016, 5, S529-S531.	0.4	0
99	Abstract 1583: Inhibition of proline isomerase Pin1 interrupts the function of the androgen receptor N-terminal domain and suppresses androgen-independent growth of prostate cancer cells. , 2017, , .		0
100	Abstract 1516: Androgen-repressed and androgen-induced genes: challenging the traditional dogma of prostate cancer therapy. , 2017, , .		0
101	Abstract 5220: Chronic exposure to a novel AR-NTD inhibitor induces resistance via a selective metabolism pathway. , 2017, , .		0
102	Abstract 1000: Targeting androgen receptors and cyclin-dependent kinases 4 and 6 in breast cancer. , 2019, , .		0
103	Abstract 1023: Combining all-trans retinoic acid therapy with androgen receptor N-terminal domain inhibitors for the treatment of castration-resistant prostate cancer. , 2019, , .		0